Targeting Th17 Cells with Small Molecules and Small Interference RNA

T helper 17 (Th17) cells play a central role in inflammatory and autoimmune diseases via the production of proinflammatory cytokines interleukin- (IL-) 17, IL-17F, and IL-22. Anti-IL-17 monoclonal antibodies show potent efficacy in psoriasis but poor effect in rheumatoid arthritis (RA) and Crohn’s d...

Full description

Saved in:
Bibliographic Details
Main Authors: Hui Lin, Pingfang Song, Yi Zhao, Li-Jia Xue, Yi Liu, Cong-Qiu Chu
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2015/290657
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849410881792770048
author Hui Lin
Pingfang Song
Yi Zhao
Li-Jia Xue
Yi Liu
Cong-Qiu Chu
author_facet Hui Lin
Pingfang Song
Yi Zhao
Li-Jia Xue
Yi Liu
Cong-Qiu Chu
author_sort Hui Lin
collection DOAJ
description T helper 17 (Th17) cells play a central role in inflammatory and autoimmune diseases via the production of proinflammatory cytokines interleukin- (IL-) 17, IL-17F, and IL-22. Anti-IL-17 monoclonal antibodies show potent efficacy in psoriasis but poor effect in rheumatoid arthritis (RA) and Crohn’s disease. Alternative agents targeting Th17 cells may be a better way to inhibit the development and function of Th17 cells than antibodies of blocking a single effector cytokine. Retinoic acid-related orphan receptor gamma t (RORγt) which acts as the master transcription factor of Th17 differentiation has been an attractive pharmacologic target for the treatment of Th17-mediated autoimmune disease. Recent progress in technology of chemical screen and engineering nucleic acid enable two new classes of therapeutics targeting RORγt. Chemical screen technology identified several small molecule specific inhibitors of RORγt from a small molecule library. Systematic evolution of ligands by exponential enrichment (SELEX) technology enabled target specific aptamers to be isolated from a random sequence oligonucleotide library. In this review, we highlight the development and therapeutic potential of small molecules inhibiting Th17 cells by targeting RORγt and aptamer mediated CD4+ T cell specific delivery of small interference RNA against RORγt gene expression to inhibit pathogenic effector functions of Th17 lineage.
format Article
id doaj-art-60d0212236cb4e17bf8762481bd377e5
institution Kabale University
issn 0962-9351
1466-1861
language English
publishDate 2015-01-01
publisher Wiley
record_format Article
series Mediators of Inflammation
spelling doaj-art-60d0212236cb4e17bf8762481bd377e52025-08-20T03:34:57ZengWileyMediators of Inflammation0962-93511466-18612015-01-01201510.1155/2015/290657290657Targeting Th17 Cells with Small Molecules and Small Interference RNAHui Lin0Pingfang Song1Yi Zhao2Li-Jia Xue3Yi Liu4Cong-Qiu Chu5Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, ChinaDivision of Arthritis and Rheumatic Diseases, Oregon Health & Science University and VA Portland Health Care System, Portland, OR 97239, USADepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, ChinaDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, ChinaDepartment of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, ChinaDivision of Arthritis and Rheumatic Diseases, Oregon Health & Science University and VA Portland Health Care System, Portland, OR 97239, USAT helper 17 (Th17) cells play a central role in inflammatory and autoimmune diseases via the production of proinflammatory cytokines interleukin- (IL-) 17, IL-17F, and IL-22. Anti-IL-17 monoclonal antibodies show potent efficacy in psoriasis but poor effect in rheumatoid arthritis (RA) and Crohn’s disease. Alternative agents targeting Th17 cells may be a better way to inhibit the development and function of Th17 cells than antibodies of blocking a single effector cytokine. Retinoic acid-related orphan receptor gamma t (RORγt) which acts as the master transcription factor of Th17 differentiation has been an attractive pharmacologic target for the treatment of Th17-mediated autoimmune disease. Recent progress in technology of chemical screen and engineering nucleic acid enable two new classes of therapeutics targeting RORγt. Chemical screen technology identified several small molecule specific inhibitors of RORγt from a small molecule library. Systematic evolution of ligands by exponential enrichment (SELEX) technology enabled target specific aptamers to be isolated from a random sequence oligonucleotide library. In this review, we highlight the development and therapeutic potential of small molecules inhibiting Th17 cells by targeting RORγt and aptamer mediated CD4+ T cell specific delivery of small interference RNA against RORγt gene expression to inhibit pathogenic effector functions of Th17 lineage.http://dx.doi.org/10.1155/2015/290657
spellingShingle Hui Lin
Pingfang Song
Yi Zhao
Li-Jia Xue
Yi Liu
Cong-Qiu Chu
Targeting Th17 Cells with Small Molecules and Small Interference RNA
Mediators of Inflammation
title Targeting Th17 Cells with Small Molecules and Small Interference RNA
title_full Targeting Th17 Cells with Small Molecules and Small Interference RNA
title_fullStr Targeting Th17 Cells with Small Molecules and Small Interference RNA
title_full_unstemmed Targeting Th17 Cells with Small Molecules and Small Interference RNA
title_short Targeting Th17 Cells with Small Molecules and Small Interference RNA
title_sort targeting th17 cells with small molecules and small interference rna
url http://dx.doi.org/10.1155/2015/290657
work_keys_str_mv AT huilin targetingth17cellswithsmallmoleculesandsmallinterferencerna
AT pingfangsong targetingth17cellswithsmallmoleculesandsmallinterferencerna
AT yizhao targetingth17cellswithsmallmoleculesandsmallinterferencerna
AT lijiaxue targetingth17cellswithsmallmoleculesandsmallinterferencerna
AT yiliu targetingth17cellswithsmallmoleculesandsmallinterferencerna
AT congqiuchu targetingth17cellswithsmallmoleculesandsmallinterferencerna